The outcome of these developments is expected to impact the entire field of antisense technology. Although other companies, including Novopharm Biotech (Winnipeg, Manitoba, Canada), Hybridon ...

As implied in the article by Paul Smaglik, "Making Sense of Antisense" (The Scientist, 12[17]:1, Aug. 31, 1998), the clinical usefulness of antisense compounds will be determined, in large part, by ...

In trials at University College London Hospitals (UCLH), an ASO is being used to target the mutated gene that results in the ...

The specificity of antisense approaches is much debated and has hampered their development for clinical therapeutics. In the August 14 Proceedings of the National Academy of Sciences, Yee Cho and ...

“This partnership will combine the category-defining expertise in antisense technology which Stan and n-Lorem have developed, with GondolaBio’s ability to rapidly and efficiently progress ...

PORTLAND, IN, UNITED STATES, January 28, 2025 /EINPresswire / -- The RNA based therapeutics has been explored as a promising treatment option for the diseases which are difficult to treat. Development ...

Equities research analysts at StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH – Get Free Report) in a report released on Wednesday. The firm set a “sell” rating on the stock.

Sanofi has entered into a collaboration and license agreement with Alloy Therapeutics to develop an antisense oligonucleotide (ASO) therapy targeting a single, undisclosed central nervous system ...